FDA pauses RAPT Therapeutics’ immunology drug studies after patient experiences liver failure
The FDA has placed a clinical hold on two trials of RAPT Therapeutics’ lead immunology candidate, zelnecirnon, the biotech announced Tuesday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
